Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Increases By 262.4%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,600,000 shares, a growth of 262.4% from the October 15th total of 441,500 shares. Based on an average daily volume of 30,810,000 shares, the short-interest ratio is presently 0.1 days. Currently, 3.9% of the company’s stock are sold short.

CERo Therapeutics Stock Performance

CERO stock traded down $0.06 during midday trading on Wednesday, reaching $0.21. 43,268,090 shares of the company’s stock traded hands, compared to its average volume of 15,191,681. The firm’s fifty day moving average price is $0.10 and its 200-day moving average price is $0.37. CERo Therapeutics has a 52 week low of $0.06 and a 52 week high of $12.80.

CERo Therapeutics (NASDAQ:CERO) last released its earnings results on Wednesday, August 14th. The company reported ($0.33) earnings per share for the quarter.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.